- Report
- March 2024
- 145 Pages
Global
From €3746EUR$3,899USD£3,216GBP
- Report
- November 2023
- 139 Pages
Global
From €3060EUR$3,185USD£2,627GBP
€4372EUR$4,550USD£3,753GBP
- Report
- January 2024
- 395 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Report
- January 2024
- 285 Pages
Global
From €9128EUR$9,500USD£7,836GBP
- Report
- August 2022
- 115 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Report
- September 2019
Global
From €5160EUR$5,370USD£4,429GBP
- Report
- January 2022
- 137 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Book
- July 2009
- 1116 Pages
Zonisamide is a sulfonamide anticonvulsant drug used to treat epilepsy and other seizure disorders. It is classified as a Central Nervous System (CNS) drug, and is used to reduce the frequency and severity of seizures. Zonisamide is also used to treat bipolar disorder, and is sometimes used as an adjunct to other medications for the treatment of depression. Zonisamide is generally well-tolerated, with few side effects. Common side effects include dizziness, drowsiness, and nausea.
The zonisamide market is a small but growing segment of the CNS drug market. It is used to treat a variety of neurological conditions, and is gaining popularity due to its effectiveness and low side effect profile. Zonisamide is available in both generic and branded forms, and is sold in both oral and injectable forms.
Some companies in the zonisamide market include Sun Pharmaceuticals, Teva Pharmaceuticals, Mylan Pharmaceuticals, and Dr. Reddy's Laboratories. Show Less Read more